Article All rights reserved
refereed
published

Knowledge gaps and research priorities in the prevention and control of hepatitis E virus infection.

ORCID
0000-0002-7498-8002
Affiliation
Wageningen Bioveterinary Research (WBVR), Lelystad, Netherlands.
Van der Poel, W. H. M.;
Affiliation
European Centre for Environment and Human Health, University of Exeter, Exeter, UK.
Dalton, H. R.;
Affiliation
German Federal Institute for Risk Assessment (BFR), Berlin, Germany.
Johne, Reimar;
Affiliation
French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Paris, France.
Pavio, N.;
Affiliation
Vion, Boxtel, Netherlands.
Bouwknegt, M.;
Affiliation
School of Public Health, Xiamen University, Xiamen, China.
Wu, T.;
Affiliation
Jorvik Food and Environmental Virology Ltd, York, UK.
Cook, N.;
Affiliation
Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
Meng, X. J.

Hepatitis E virus (HEV), family Hepeviridae, is a main cause of epidemic hepatitis in developing countries and sporadic and cluster cases of hepatitis in industrialized countries. There are an increasing number of reported cases in humans especially in industrialized countries, and there is a high potential for transboundary spread of zoonotic genotypes of the virus through the transport of pigs, pig products and by-products. Bloodborne transmission of the virus has been reported with a significant medical concern. To better coordinate HEV research and design better control measures of HEV infections in animals, a group of HEV experts reviewed the current knowledge on the disease and considered the existing disease control tools. It was concluded that there is a lack of in-depth information about the spread of the virus from pigs to humans. The role of animals other than pigs in the zoonotic transmission of the virus to humans and the extent of foodborne transmission are poorly understood. Factors involved in development of clinical disease such as infectious dose, susceptibility and virulence of virus strains need to be studied more extensively. However, such studies are greatly hindered by the absence of a broadly applicable, efficient and sensitive in vitro cell culture system for HEV. Diagnostic tools for HEV are available but need to be further validated, harmonized and standardized. Commercially available HEV vaccines for the control of HEV infection in animal populations are needed as such vaccines can minimize the zoonotic risk for humans. Anti-HEV drugs for treatment of HEV-infected patients need to be studied more extensively. The detailed expert review can be downloaded from the project website at http://www.discontools.eu/.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

Use and reproduction:
All rights reserved